Cologuard earns positive review from Blue Cross Blue Shield Association

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Exact Sciences Corp. announced that the Blue Cross Blue Shield Association’s Center for Clinical Effectiveness “Evidence Street” recently released a positive review of Cologuard to its members.

This continues the positive momentum for Cologuard, as coverage increased by 67 percent in 2016 and nearly 163 million Americans are now in health plans that cover the non-invasive colorectal cancer screening option.

“Nearly two thirds of the Blue Cross and Blue Shield companies already cover Cologuard,” said Kevin Conroy, Exact Sciences’ chairman and CEO. “This review affirms that Cologuard has a positive impact on health outcomes and provides additional support for the remaining plans to offer their members our patient-friendly, non-invasive colon cancer screening option.”

The BCBSA’s Center for Clinical Effectiveness is an organization that assesses the effectiveness of medical devices, procedures, and biological products through comprehensive reviews and clinical evidence. The Evidence Street assessment follows other positive reviews of Cologuard, which is now included in the recommendations of the U.S. Preventive Services Task Force, and the colorectal cancer screening guidelines of the American Cancer Society and the National Comprehensive Cancer Network.

More than 70 percent of Cologuard’s addressable population is now in a health plan that covers the test, the company said. Coverage expanded by 62 million lives since June 2016, when Cologuard was included as an A-graded test in the U.S. Preventive Services Task Force’s final colorectal cancer screening recommendations.

Table of Contents

YOU MAY BE INTERESTED IN

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.” 

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community.  The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login